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Introduction: Osteopetrosis is a rare inherited genetic disease characterized by sclerosis of the skeleton. The
absence or malfunction of osteoclasts is found to be strongly associated with the disease evolution. Currently, four
clinically distinct forms of the disease have been recognized: the infantile autosomal recessive osteopetrosis, the
malignant and the intermediate forms, and autosomal dominant osteopetrosis, type I and type II forms. The
autosomal recessive types are the most severe forms with symptoms in very early childhood, whereas the
autosomal dominant classes exhibit a heterogeneous trait with milder symptoms, often at later childhood or
adulthood.
Case presentation: Case 1 is the 12-year-old daughter (index patient) of an Iraqi-Kurdish family who, at the age of
eight years, was diagnosed clinically to have mild autosomal dominant osteopetrosis. Presently, at 12-years old, she
has severe complications due to the disease progression. In addition, the same family previously experienced the
death of a female child in her late childhood. The deceased child had been misdiagnosed, at that time, with
thalassemia major. In this report, we extended our investigation to identify the type of the inheritance patterns of
osteopetrosis using molecular techniques, because consanguineous marriages exist within the family history. We
have detected one heterozygous mutation in exon 15 of the Chloride Channel 7 gene in the index patient (Case 1),
whereas other mutations were not detected in the associated genes TCIRG1, OSTM1, RANK, and RANKL. The
missense mutation (CGG>TGG) located in exon 15 (c.1225C>T) of the Chloride Channel 7 gene changed the amino
acid position 409 from arginine to tryptophan (p.R409W, c.1225C>T).
Case 2 is the 16-year-old son (brother of the index patient) of the same family who was diagnosed clinically with mild
autosomal dominant osteopetrosis. We have identified the same heterozygous mutation in exon 15 of the Chloride
channel 7 gene in this patient (Case 2). The missense mutation (CGG>TGG) located in exon 15 (c.1225C>T) of the
Chloride channel 7 gene changed the amino acid position 409 from arginine to tryptophan (p.R409W, c.1225C>T).
In addition to the clinical diagnosis of both cases, the missense mutation we identified in one allele of the Chloride
channel 7 gene could be linked to autosomal dominant osteopetrosis-II because the symptoms appear in late
childhood or adolescence.
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Conclusion: In this family, the molecular diagnosis was confirmed after identification of the same mutation in the
older son (sibling). Furthermore, we detected that the father and his brother (the uncle) are carriers of the same
mutation, whereas the mother and her sister (the aunt) do not carry any mutation of the Chloride channel 7 gene. Thus,
the disease penetrance is at least 60% in the family. The mother and father are cousins and a further consanguineous
marriage between the aunt and the uncle is not recommended because the dominant allele of the Chloride channel 7
gene will be transferred to the progeny. However, a similar risk is also expected following a marriage between the
uncle and an unrelated woman. The p.R409W mutation in the Chloride channel 7 gene has not yet been described in
the literature and it possibly has a dominant-negative impact on the protein.
Keywords: Autosomal dominant osteopetrosis, CLCN7 gene, Consanguineous marriage, Dominant allele, OsteopetrosisIntroduction
Osteopetrosis (OP) is a clinically and genetically hetero-
geneous group of diseases characterized by a symmet-
rical increase in bone density [1,2]. The sclerosis of bone
is due to the absence of or to a defect in osteoclast bone
resorption. The overall incidence of these conditions,
dependent on the disease forms, varies from 1:20,000 to
1:250,000 [1-3].
The severity of the presentation of OP in infancy var-
ies from asymptomatic to fatal and can be grouped into
autosomal recessive (ARO) and autosomal dominant
(ADO) [1-3]. The severest forms tend to have autosomal
recessive inheritance, whereas the mildest forms are
inherited in an autosomal dominant manner [3,4]. The
malignant and intermediate form of ARO is a life-
threatening condition and the disease is manifested in
infancy and early childhood [1,3]. The benign ADO typ-
ically has an onset in late childhood or adolescence [1,3]
and can be subdivided into three subclasses: benign type
I (ADO-I), benign type II (ADO-II), and benign type III
(ADO-III) [1,5,6]. ADO-I is generally very mild with a
diffuse sclerosis without alterations in the bone turnover.
Genetic mutations of Low-density lipoprotein receptor-
related protein 5 gene were identified to be responsible
for ADO-I [7,8], thus causing an increased bone forma-
tion ‘high bone density’ rather than a decreased bone re-
sorption [7,8]. This phenotype is not associated with an
increased fracture rate and is reported to be fully pene-
trant [9], whereas ADO-II has an extremely heteroge-
neous course ranging from an asymptomatic to a severe
phenotype. ADO-II is the most common form; it is char-
acterized by thickness of the vertebral end plates (sand-
wich vertebrae or rugger jersey spine) and the bone
within the bone, and is most commonly noted in the
pelvis, vertebrae and at the ends of long bones. ADO-II
is associated with diffuse pain, hematological and neural
failure, osteomyelitis and frequent pathological fractures.
Early death in patients with ADO-II is rare, but some
patients can experience a very poor quality of life [10].
In 1904, Albers-Schönberg was the first to describe a
case of OP [11], which is an identical OP phenotype toADO-II symptoms. ADO-III or centrifugal OP has been
described in a Vietnamese family; this type is predomin-
antly characterized by sclerosis of the distal appendicular
skeleton and the skull, but with minor involvement of
the axial skeleton [12].
The families of Chloride channel (CLC) proteins have
received considerable attention, often with surprising
developments, over the past five years [13], and their
physiological roles are impressively illustrated by various
inherited human diseases and knockout mouse models
[14]. The Chloride channel 7 (CLCN7) gene is a member
of the mammalian CLC gene family [14]. In osteoclasts,
the Chloride channel 7 (CLC7) protein resides in the late
endocytotic–lysosomal pathway of the ruffled membrane
borders and is involved in the acidification of the resorp-
tion lacunae. The physiological function of the CLC7
protein was unclear until Kornak showed that the dis-
ruption of the CLCN7 gene in mice causes severe OP,
and that the CLC7 protein played an essential role in the
acidification of the extracellular resorption lacunae,
which is very important for osteoclast-mediated resorp-
tion of mineralized bone [15]. In humans, mutations in
the CLCN7 gene give rise to the complete spectrum of
OP phenotypes, ranging from malignant and intermedi-
ate forms of ARO to ADO-II and even asymptomatic
ADO-II cases [16-21]. Indeed, the complete clinical and
molecular analysis of several patients found novel muta-
tions, including missense, frameshift, nonsense, deletion
and splice-site defects [20-22].
The first successful bone marrow (BM) transplantation
for OP patients was in 1977 [23,24]. At that time, the bio-
logical origin of osteoclasts and osteoblasts was unknown.
The OP patients were successfully treated by bone BM
transplantation, from the availability of compatible donors
of osteoclasts and a mixture of hematopoietic lineages.
This was later confirmed experimentally [25]. BM trans-
plantation is a drastic treatment and it is applied only to
children severely affected by OP. If it is successful, it will
save the life of a child who would otherwise die from the
disease progression, which results in growth retardation
and neurological defects. Development of hematopoietic
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for this disease due to the elimination of rejection risks
[26]. In the future, an alternative approach that holds the
potential for the permanent cure of OP is in utero prenatal
HSTC (for review see [27]).
Case presentation
Case 1
A Kurdish family in Sulaimaniyah city (Kurdistan Region,
Iraq) has been identified with a history of OP in sib-
lings. Currently, the family has two children: one affected
12-year-old girl (Case 1), and a 16-year-old boy (Case 2)
with milder symptoms of OP. The index patient (Case 1),
already diagnosed at the age of eight years with a mild OP
phenotype, has now developed a severe form of OP. She is
currently reaching the end-stage due to the disease pro-
gression: she has anemia, diffuse cutaneous ecchymosis
with gum bleeding and recurrent epistaxis, and chest
infections. All these clinical features are due to the reduc-
tion of BM function and BM cavity. Moreover, she com-
plains of right-sided conductive deafness and a severe
reduction in visual acuity due to compression on theFigure 1 X-rays and computed tomography scan image of the patien
endplate thickening (sandwich vertebrae sign) of the rib and vertebrae, (B)
homogenous sclerotic skull bones. (D) A computed tomography scan imag
homogenously sclerotic skull bones encroaching on both optic foramens, a
fourth ventricle.cranial nerves. In addition, the family also has a previous
history of a daughter with secondary anemia, bleeding
tendency, and splenomegaly in her late childhood. She
was wrongly diagnosed with thalassemia major at that
time prior to her death. Therefore, we decided to screen
for the possible mutated gene(s) often associated with
OP and determine inheritance pattern for the disease
development. We prepared genomic deoxyribonucleic
acid (DNA) from peripheral blood samples obtained
from the whole family, consisting of father, mother,
son, the surviving daughter (Case 1) together with a
paternal uncle and a maternal aunt. The peripheral blood
samples were preserved in ethylenediaminetetraacetic
acid, then the genomic DNA was extracted using the
Qiagen Genome DNA kit.
The index patient (Case 1) often complained of back
pains. Skeletal radiography (Figure 1A-C) showed a diffuse
increase in bone density with evidence of a sandwich ap-
pearance in the vertebrae and iliac wings (bone-in-bone).
The computed tomography (CT) scan (Figure 1D) showed
increased thickened bone density, homogenously sclerotic
skull bones, encroaching on both optic foramens, andt showing bone thickening. Radiograph shows typical (A) vertebral
diffuse thickening of pelvic and lower limb bones, and (C)
e of the patient’s brain showing an increased thickened bone density,
nd mild dilatation of the lateral and third ventricle with normal
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Case 2
The same Kurdish family in Sulaimaniyah city (Kurdistan
Region, Iraq) has a 16-year-old boy (Case 2) with milder
symptoms of OP. The milder grade patient (Case 2) has
generally been in good health, but has reported a decline
in his visual acuity over the past two years. A clinical la-
boratory diagnosis was determined for the core family as
summarized in Table 1. The results of the laboratory tests
clearly show that hemoglobin (Hb), white blood cells
(WBCs) and platelet cells are most affected in the index
patient (Case 1) in comparison to the parents (Table 1).
Other clinical observations show declined organ functions
in the index patient compared with normal healthy indivi-
duals (Table 2). It is worth mentioning that the reference
values for these parameters are not age dependent. There-
fore, the data comparison between patients (Case 1 and
Case 2) and healthy parents is valid.
Discussion
The scleroses of bone in patients are often asymptomatic
at an early stage and the precise diagnosis is clinical and
largely depends on the radiographic appearance of the
skeleton. The radiographic appearance exhibits a dif-
fused sclerosis in skull, spine, pelvis and appendicular
bones, and a funnel-like appearance and characteristic
lucent bands at the metaphysis of the long bones that re-
sult from defects of bone remodeling [3]. Other features
are also observed, such as bone-in-bone appearance, and
focal sclerosis of the skull base, pelvis and vertebral end
plates [3]. In other cases the diagnosis may be reachedTable 1 The results of laboratory tests for core family membe
with mild-form symptoms (Case 2) and the parents
Test Case 1
Hemoglobin (g/dL) (8)
White blood cell (1000 × cell/dL) (3.5)
Platelet (1000 × cell/dL) (20)
Blood sugar (mg/dL) 82
Blood urea (mg/dL) 26
Serum creatinine (mg/dL) 1.1
Serum calcium (mg/dL) 8.1
Serum phosphorous (ng/dL) 4.0
Serum alkaline phosphate (IU/L) 261
Serum alanine transaminase (IU/L) 17
Serum aspartate transaminase (IU/L) 30
Total serum bilirubin (mg/dL) 1.0
Parathyroid hormone (pg/mL) 35
Serum lactate dehydrogenase (IU/mL) 416
NV, the range of normal values in healthy individuals, the parents. The bold numbe
reference range.by chance [28]. In the absence of typical radiographic
findings, raised creatine kinase BB isoenzyme and
tartrate-resistant acid phosphatase (TRAP) can be help-
ful in making a diagnosis of ADO [29-31]. However, by
systematic investigations, in our case, we have diagnosed
the patients’ manifestations as related to ADO-II. Our
diagnosis was based on clinical symptoms, radiographic
appearance and laboratory analysis. The laboratory data
(Table 1) showed normal range of serum sugar, urea,
creatinine, phosphorus, calcium, bilirubin, alanine trans-
aminase, aspartate transaminase, lactate dehydrogenase
and parathyroid hormone for all the family members,
except a slight elevation in serum alkaline phosphatase
for the brother (Case 2) who has milder symptoms
(Table 1). However, we did not analyze creatine kinase
BB isoenzyme and TRAP because of the absence of
these assays in our locality. The index patient (Case 1)
showed lower values for Hb and WBC, and her platelet
count was diminished by a factor of 10 (Table 1). There-
fore, the index patient (Case 1) showed anemia and
thrombocytopenia, whereas the blood examination was
normal for other family members (Table 1).
Next, we performed genetic analysis for the whole
family, including an aunt and an uncle, in order to link
the disease-type with a possible gene(s) mutation and to
find out the origin of the inherited condition. We
wanted to address possible risks for the development of
the disease in children born within the family in the fu-
ture because the parents are cousins, and because there
is the possibility of other consanguineous marriages in-
volving the aunt and the uncle. With these notations, we
decided to help the family to perform genetic counseling
in this particular case.rs: the daughter with severe symptoms (Case 1), the son
Case 2 Mother Father NV
13 12 14 12–16
9.0 6.0 8.5 4.0–11.0
240 210 200 150–400
88 86 282 74–110
28 22 25 14–50
1.0 1.1 1.3 0.2–1.2
9.5 8.2 9.2 8.1–10.4
3.0 2.8 2.7 2.5–5.0
515 284 218 100–320
44 35 36 <45
45 40 38 <35
0.4 0.4 0.7 0.2–1.2
32 16 25 10–65
246 200 206 150–500
rs in parenthesis under Case 1 represent values outside of the normal
Table 2 Other clinical manifestations of the children
(Case 1 and Case 2) and healthy parents
Test Case 1 Case 2 Mother Father























Figure 2 Electropherogram results of CLCN7 exon 15
sequencing derived from a family with a history of autosomal
dominant osteopetrosis-II and a control individual. The
c.1225C>T position is indicated. Codon CGG is changed to TGG
(p.Arg409Trp).
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genes most commonly associated with OP: TCIRG1,
CLCN7, OSTM1, RANK and RANKL. The six members of
the family, including the parents of the minors, gave
written informed consent to participate in this analysis.
From the genomic DNA, the coding regions of the above
five genes were amplified using the polymerase chain reac-
tion (PCR) method. Complete DNA sequencing on each
PCR product was performed and a missense mutation was
found at exon 15 of the CLCN7 gene (Figure 2). In the
index patient, sequencing of the other associated genes
revealed coding sequences for wild-type protein. There-
fore, other family members were exclusively screened for
mutation at exon 15 of the CLCN7 gene (Figure 2).
When the whole coding regions of the CLCN7 gene
were analyzed for the index patient (daughter), a unique
heterozygous missense mutation (CGG>TGG) in exon
15 (c.1225C>T) was detected (Figure 2), which changes
the amino acid position 409 from arginine to tryptophan
of the CLC7 protein (p.R409W). Although the mother
and the aunt displayed a wild-type (p.Arg409) amino
acid for the CLC7 protein, all the other family members
had the heterozygous mutation p.Arg409Trp (Figure 2
and Table 3). The missense mutation (p.Arg409Trp)
found in this work is unique and has not yet been
described in the published literature. It has previously
been found that the heterozygous mutation in the
CLCN7 gene is linked to benign ADO (ADO-II) symp-
toms [20,21], because mild symptoms appear in early
childhood and worsen over time with life-threatening
complications. These features have been historically
experienced within the family: one child died at age 10
years, another child (index patient) has ADO-II progres-
sion at the age of 12 years, whereas their 16-year-old
brother had no obvious symptoms at early childhood
but clinical features have now started to appear inrelation to ADO-II. Our genetic findings of the mutation
CLCN7 gene confirm that the brother is also at risk of
developing ADO-II complications.
Molecular and clinical findings have shown that vari-
ous mutations in the CLCN7 gene lead to the develop-
ment of various types of OP, from asymptomatic to
severe forms [15,17,20,21,32]. Mice with a disruption of
the corresponding gene CLCN7 showed severe OP,
retinal degeneration, and they only live for between five
and seven weeks [33]. In humans it was also noted that
homozygous mutation in the CLCN7 gene causes
Table 3 Unique heterozygous mutation in the CLCN7
gene found in the family
Samples Family member Mutation status of the CLCN7
gene C1255T (R409W)
1 Mother Wild type
2 Father Heterozygous
3 Daughter
(index patient, Case 1)
Heterozygous
4 Brother (mild carrier, Case 2) Heterozygous
5 Uncle Heterozygous
6 Aunt Wild type
7 Control Wild type
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gous for dominant-negative mutations have a less severe
form of ADO-II [32]. It is known that ADO-II symptoms
are not homogenous and have wide clinical manifestations
from asymptomatic to severe [31,34]. Large scale geno-
type–phenotype correlation analysis of CLCN7-dependent
ARO cases and ADO-II cases probably does not supportFigure 3 Family pedigree analysis, in which three individuals (childre
osteopetrosis-II, while the father and the uncle are carriers. One of the
carrier (Case 2, a boy at age 16 years) and the index patient has severe symthe haploinsufficiency mechanism, rather the hypothesis
has to be validated experimentally with biochemical assays
[20]. This suggests to us that either the father or the uncle
might develop ADO-II symptoms in late adulthood, or
they might live a normal life without any obvious ADO-II
phenotype. The genetic findings in this work allows us to
perform pedigree analysis, indicating the origin of inherit-
ance to be common for the father and uncle (Figure 3).
Conclusions
In this study, we report a case of a Kurdish family
affected by an OP phenotype with broad severity, and
diagnosed using complete clinical management, labora-
tory analysis, and treatment in our locality. We have
identified a novel missense mutation (p.R409W) in exon
15 of the CLCN7 gene as responsible for ADO-II in the
12-year-old index patient and her 16-year old brother;
their father is a seemingly healthy carrier of the muta-
tion. Our results show that the uncle (father’s brother) is
also a carrier indicating that another possible consan-
guineous marriage between the aunt (mother’s sister)n) are or have been affected by autosomal dominant
affected children has died (girl at age 11 years), another is a mild
ptoms (Case 1, a girl at age 12 years).
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very probable that their progeny would develop ADO-II
because they will carry an inherited mutated allele of the
CLCN7 gene. Although unidentified genetic variants might
exist, a marriage between the uncle-carrier and an unre-
lated woman could also develop risks similar to those of his
marriage to the non-carrier aunt. However, the complete
genotype–phenotype correlation remains obscure, even
though one allele of the CLCN7 gene was found to be
mutated. Discovery of a specific biochemical assay marker
is required to quantify the actual CLC activity of the CLC7
protein that might support diagnosis more precisely to cor-
relate the CLC function to the disease forms.
Consent
Written informed consent was obtained from the parents
to report the case together with any accompanying
images. A scanned-original copy of the written consent is
available for review by the Editor-in-Chief of this journal.
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